替西肽的减肥效果及其与炎性肠病减肥手术的比较效果。

IF 2.1 Q3 GASTROENTEROLOGY & HEPATOLOGY

Indian Journal of Gastroenterology Pub Date : 2025-07-19 DOI:10.1007/s12664-025-01835-y

Aakash Desai, Himsikhar Khataniar, Fjona Tabaku, Jana G Hashash, Francis A Farraye, Gursimran S Kochhar

{"title":"替西肽的减肥效果及其与炎性肠病减肥手术的比较效果。","authors":"Aakash Desai, Himsikhar Khataniar, Fjona Tabaku, Jana G Hashash, Francis A Farraye, Gursimran S Kochhar","doi":"10.1007/s12664-025-01835-y","DOIUrl":null,"url":null,"abstract":"Background and aims: There is limited data about tirzepatide's (TZP) efficacy for weight loss in patients with inflammatory bowel disease (IBD).Methods: A retrospective cohort study was conducted using the US Collaborative Network in patients with IBD on TZP between January 5, 2022 and December 31, 2023. The objective was to assess mean total body weight (TBW) change in pounds (lbs) in the IBD TZP cohort compared to the non-IBD TZP cohort and IBD cohort with weight loss surgery (WLS) from baseline to between six and 15 months. 1:1 propensity score matching was performed for demographics, comorbid conditions, body mass index (BMI) and body weight.Results: There were 274 patients in the IBD TZP cohort (mean age 53.6 ± 11.9, 66.4% diabetes mellitus, BMI 38.3 ± 7.7 kg/m2). There was no difference in the TBW change between the IBD and non-IBD cohort on TZP (-21 lbs [ 95% CI -30 to -12] vs. -21 lbs [-30 to -11], p = 1.0). There was no difference in the TBW based on time interval, IBD type, IBD medications, surgery and TZP dose. There was a lower TBW change compared to the IBD WLS cohort (-21 lbs [-36 to -5] vs. -55 lbs [-68 to -41], p < 0.0001). There was higher TBW change with 15 mg TZP (-29 lbs [-45 to -12]) compared to 5-10 mg TZP (-15 lbs [-36 to 6]), however, lower compared to the IBD WLS cohort.Conclusion: TZP use was associated with a similar mean weight loss of > 10% in patients with IBD compared to patients without IBD, however lower compared to WLS.","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of tirzepatide for weight loss and it's comparative effectiveness to weight loss surgery in inflammatory bowel disease.\",\"authors\":\"Aakash Desai, Himsikhar Khataniar, Fjona Tabaku, Jana G Hashash, Francis A Farraye, Gursimran S Kochhar\",\"doi\":\"10.1007/s12664-025-01835-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and aims: There is limited data about tirzepatide's (TZP) efficacy for weight loss in patients with inflammatory bowel disease (IBD).Methods: A retrospective cohort study was conducted using the US Collaborative Network in patients with IBD on TZP between January 5, 2022 and December 31, 2023. The objective was to assess mean total body weight (TBW) change in pounds (lbs) in the IBD TZP cohort compared to the non-IBD TZP cohort and IBD cohort with weight loss surgery (WLS) from baseline to between six and 15 months. 1:1 propensity score matching was performed for demographics, comorbid conditions, body mass index (BMI) and body weight.Results: There were 274 patients in the IBD TZP cohort (mean age 53.6 ± 11.9, 66.4% diabetes mellitus, BMI 38.3 ± 7.7 kg/m2). There was no difference in the TBW change between the IBD and non-IBD cohort on TZP (-21 lbs [ 95% CI -30 to -12] vs. -21 lbs [-30 to -11], p = 1.0). There was no difference in the TBW based on time interval, IBD type, IBD medications, surgery and TZP dose. There was a lower TBW change compared to the IBD WLS cohort (-21 lbs [-36 to -5] vs. -55 lbs [-68 to -41], p < 0.0001). There was higher TBW change with 15 mg TZP (-29 lbs [-45 to -12]) compared to 5-10 mg TZP (-15 lbs [-36 to 6]), however, lower compared to the IBD WLS cohort.Conclusion: TZP use was associated with a similar mean weight loss of > 10% in patients with IBD compared to patients without IBD, however lower compared to WLS.\",\"PeriodicalId\":13404,\"journal\":{\"name\":\"Indian Journal of Gastroenterology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-07-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12664-025-01835-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12664-025-01835-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景和目的：关于替西帕肽（TZP）对炎症性肠病（IBD）患者减肥效果的数据有限。方法：在2022年1月5日至2023年12月31日期间，使用美国协作网络对IBD患者进行回顾性队列研究。目的是评估IBD TZP组与非IBD TZP组和IBD减重手术组（WLS）从基线到6至15个月的平均总体重（TBW）磅（lbs）变化。对人口统计学、合并症、身体质量指数（BMI）和体重进行1:1倾向评分匹配。结果：IBD TZP队列274例患者（平均年龄53.6±11.9岁，糖尿病患者66.4%,BMI 38.3±7.7 kg/m2）。使用TZP治疗的IBD和非IBD患者的TBW变化无差异（-21磅[95% CI -30至-12]vs. -21磅[-30至-11]，p = 1.0）。TBW在时间间隔、IBD类型、IBD药物、手术和TZP剂量方面无差异。与IBD WLS组相比，TBW的变化更低（-21磅[-36至-5]vs -55磅[-68至-41]）。结论：与非IBD患者相比，使用TZP与IBD患者的平均体重减轻相似，为1010%，但与WLS组相比较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy of tirzepatide for weight loss and it's comparative effectiveness to weight loss surgery in inflammatory bowel disease.

Background and aims: There is limited data about tirzepatide's (TZP) efficacy for weight loss in patients with inflammatory bowel disease (IBD).

Methods: A retrospective cohort study was conducted using the US Collaborative Network in patients with IBD on TZP between January 5, 2022 and December 31, 2023. The objective was to assess mean total body weight (TBW) change in pounds (lbs) in the IBD TZP cohort compared to the non-IBD TZP cohort and IBD cohort with weight loss surgery (WLS) from baseline to between six and 15 months. 1:1 propensity score matching was performed for demographics, comorbid conditions, body mass index (BMI) and body weight.

Results: There were 274 patients in the IBD TZP cohort (mean age 53.6 ± 11.9, 66.4% diabetes mellitus, BMI 38.3 ± 7.7 kg/m²). There was no difference in the TBW change between the IBD and non-IBD cohort on TZP (-21 lbs [ 95% CI -30 to -12] vs. -21 lbs [-30 to -11], p = 1.0). There was no difference in the TBW based on time interval, IBD type, IBD medications, surgery and TZP dose. There was a lower TBW change compared to the IBD WLS cohort (-21 lbs [-36 to -5] vs. -55 lbs [-68 to -41], p < 0.0001). There was higher TBW change with 15 mg TZP (-29 lbs [-45 to -12]) compared to 5-10 mg TZP (-15 lbs [-36 to 6]), however, lower compared to the IBD WLS cohort.

Conclusion: TZP use was associated with a similar mean weight loss of > 10% in patients with IBD compared to patients without IBD, however lower compared to WLS.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian Journal of Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

3.90

自引率

10.00%

发文量

期刊介绍： The Indian Journal of Gastroenterology aims to help doctors everywhere practise better medicine and to influence the debate on gastroenterology. To achieve these aims, we publish original scientific studies, state-of -the-art special articles, reports and papers commenting on the clinical, scientific and public health factors affecting aspects of gastroenterology. We shall be delighted to receive articles for publication in all of these categories and letters commenting on the contents of the Journal or on issues of interest to our readers.